Opioid Approval Delay? Class REMS Poses Legal Questions For Pending Drugs, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of New Drugs Director John Jenkins explains the agency’s options in approving pending potent opioids in lieu of a class-wide REMS.